|
A blood test to identify prostate cancer patients at risk for visceral metastasis
|
5R01CA218356-02
|
$601,750
|
POSADAS, EDWIN
|
CEDARS-SINAI MEDICAL CENTER
|
|
A Genetic Toolbox for the Identification and Interrogation of Tumor Cells of Origin, Propagation, and Recurrence From Patient-derived Oncogenic Drivers
|
5R33CA202900-03
|
$418,127
|
BREUNIG, JOSHUA
|
CEDARS-SINAI MEDICAL CENTER
|
|
A Patient-Centered Approach to Integration of Life Expectancy into Treatment Decision Making for Patients with Genitourinary Malignancy
|
1K08CA230155-01
|
$183,258
|
DASKIVICH, TIMOTHY
|
CEDARS-SINAI MEDICAL CENTER
|
|
Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical Trials
|
1U01CA232859-01
|
$732,973
|
ROGATKO, ANDRE
|
CEDARS-SINAI MEDICAL CENTER
|
|
Bladder Fiducial Markers and Diffusion-MRI to Optimize Bladder Chemo-Radiotherapy
|
5R01CA201709-03
|
$724,638
|
GARCIA, MAURICE
|
CEDARS-SINAI MEDICAL CENTER
|
|
Cancer-Associated Fibroblasts Alter the Composition of B Cells I Solid Malignancies - Diversity Supplement
|
3R01CA208753-03S1
|
$106,651
|
ORSULIC, SANDRA
|
CEDARS-SINAI MEDICAL CENTER
|
|
Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies
|
5R01CA208753-03
|
$400,313
|
ORSULIC, SANDRA
|
CEDARS-SINAI MEDICAL CENTER
|
|
Connecting Genomic Alterations in Liposarcomas with Drug Responses and Identification of New Therapeutic Approaches
|
5R01CA200992-03
|
$363,125
|
KOEFFLER, HAROLD
|
CEDARS-SINAI MEDICAL CENTER
|
|
Corrole nanobiologics for targeting resistant and metastatic tumors
|
5R01CA140995-08
|
$415,625
|
MEDINA-KAUWE, LALI
|
CEDARS-SINAI MEDICAL CENTER
|
|
Design of Cancer Phase I/II Clinical Trials Using Drug Combinations of Cytotoxic and Biologic Agents
|
5R01CA188480-05
|
$352,750
|
TIGHIOUART, MOURAD
|
CEDARS-SINAI MEDICAL CENTER
|
|
Differential MRI imaging for brain tumor metastases diagnosis and treatment monitoring
|
5R01CA188743-04
|
$497,850
|
LJUBIMOVA, JULIA
|
CEDARS-SINAI MEDICAL CENTER
|
|
Functional Effects of Ovarian Cancer Risk Variants
|
3R01CA211707-02S1
|
$149,945
|
GAYTHER, SIMON
|
CEDARS-SINAI MEDICAL CENTER
|
|
Functional Effects of Ovarian Cancer Risk Variants
|
5R01CA211707-02
|
$622,079
|
GAYTHER, SIMON
|
CEDARS-SINAI MEDICAL CENTER
|
|
Glial tumor image-guided surgery and treatment
|
5R01CA209921-03
|
$519,467
|
HOLLER, EGGEHARD
|
CEDARS-SINAI MEDICAL CENTER
|
|
Gut-Related Markers and Hepatocellular Cancer in a Multi-Ethnic Cirrhotic Cohort
|
5R01CA204145-03
|
$260,399
|
HUSSAIN, SHEHNAZ
|
CEDARS-SINAI MEDICAL CENTER
|
|
High resolution volumetric MRI for prostate cancer active surveillance
|
5R01CA217098-02
|
$379,039
|
KIM, HYUNG
|
CEDARS-SINAI MEDICAL CENTER
|
|
High-throughput palmitoyl-proteomics profiling of extracellular vesicles for identification of biomarkers for early detection of clinically significant prostate cancer
|
5R01CA218526-02
|
$384,283
|
DI VIZIO, DOLORES
|
CEDARS-SINAI MEDICAL CENTER
|
|
Identification of microbial biomarkers for hepatocellular carcinoma in a multi-ethnic population of patients with nonalcoholic fatty liver disease
|
1R21CA225623-01
|
$176,514
|
HUSSAIN, SHEHNAZ
|
CEDARS-SINAI MEDICAL CENTER
|
|
Impact of the Microbiome on the Efficacy of Radiation Therapy
|
5R01CA220000-02
|
$350,000
|
SHIAO, STEPHEN
|
CEDARS-SINAI MEDICAL CENTER
|
|
Investigation and functional characterization of new drivers of mesenchymal tumorigenesis.
|
4R00CA212200-03
|
$249,000
|
GUARNERIO, JLENIA
|
CEDARS-SINAI MEDICAL CENTER
|
|
Mechanisms of gene amplification in human cancers
|
2R01CA149385-06A1
|
$363,375
|
TANAKA, HISASHI
|
CEDARS-SINAI MEDICAL CENTER
|
|
Nanoconjugate delivery of proliferation and checkpoint inhibitors to treat glial tumors
|
5R01CA206220-03
|
$547,857
|
LJUBIMOVA, JULIA
|
CEDARS-SINAI MEDICAL CENTER
|
|
Omics Approach to Interrogating Mechanism of ETV5 in Glioma
|
5F31CA213926-02
|
$38,124
|
PARK, HANNAH
|
CEDARS-SINAI MEDICAL CENTER
|
|
Pathophysiology, Epidemiology, and Prevention of Pancreatogenic Diabetes
|
5U01DK108314-04
|
$190,000
|
PANDOL, STEPHEN
|
CEDARS-SINAI MEDICAL CENTER
|
|
Predicting the diagnosis of pancreatic cancer by leveraging big data
|
1R21CA220073-01A1
|
$203,197
|
JEON, CHRISTIE
|
CEDARS-SINAI MEDICAL CENTER
|
|
PROHIBITIN 1 IN LIVER INJURY AND CANCER
|
5R01CA172086-05
|
$312,404
|
LU, SHELLY
|
CEDARS-SINAI MEDICAL CENTER
|
|
Prostate Cancer Bone Metastasis Biology and Targeting
|
3P01CA098912-14S1
|
$18,678
|
CHUNG, LELAND
|
CEDARS-SINAI MEDICAL CENTER
|
|
Prostate Cancer Bone Metastasis Biology and Targeting
|
3P01CA098912-14S2
|
$12,477
|
CHUNG, LELAND
|
CEDARS-SINAI MEDICAL CENTER
|
|
Prostate Cancer Bone Metastasis Biology and Targeting
|
5P01CA098912-14
|
$1,636,904
|
CHUNG, LELAND
|
CEDARS-SINAI MEDICAL CENTER
|
|
Protein-DNA Drug Carriers for Targeting Drug-Resistant Tumors
|
5R01CA129822-08
|
$374,063
|
MEDINA-KAUWE, LALI
|
CEDARS-SINAI MEDICAL CENTER
|
|
Qualifying Multi-Transcript Signatures for Active Surveillance of Prostate Cancer
|
3R01CA182438-05S1
|
$95,249
|
KIM, HYUNG
|
CEDARS-SINAI MEDICAL CENTER
|
|
Qualifying Multi-Transcript Signatures for Active Surveillance of Prostate Cancer
|
5R01CA182438-05
|
$548,878
|
KIM, HYUNG
|
CEDARS-SINAI MEDICAL CENTER
|
|
Racial Differences in Prostate Cancer Molecular Subtyping
|
1R01CA220327-01A1
|
$400,313
|
FREEMAN, MICHAEL
|
CEDARS-SINAI MEDICAL CENTER
|
|
Regulation and Targeting of CD24 in Bladder Cancer
|
7R01CA075115-20
|
$357,944
|
THEODORESCU, DAN
|
CEDARS-SINAI MEDICAL CENTER
|
|
Statin Intervention to Slow the Time to Hepatocellular Carcinoma Recurrence in Cirrhotics Awaiting Liver Transplantation
|
5R01CA218486-02
|
$661,266
|
HUSSAIN, SHEHNAZ
|
CEDARS-SINAI MEDICAL CENTER
|
|
The Impact of Macrophage Polarization on the Efficacy of Radiation Therapy
|
5K08CA191139-04
|
$176,796
|
SHIAO, STEPHEN
|
CEDARS-SINAI MEDICAL CENTER
|
|
The Role of FOXCI in Basal-like Breast Cancer
|
2R01CA151610-06
|
$415,527
|
CUI, XIAOJIANG
|
CEDARS-SINAI MEDICAL CENTER
|
|
The Role of Splice Quantitative Traits in Ovarian Cancer Pathogenesis
|
5R21CA220078-02
|
$181,178
|
LAWRENSON, KATE
|
CEDARS-SINAI MEDICAL CENTER
|
|
Understanding the AGL metastasis suppressor for therapeutic gain
|
3R01CA143971-08S1
|
$149,644
|
THEODORESCU, DAN
|
CEDARS-SINAI MEDICAL CENTER
|
|
Understanding the AGL metastasis suppressor for therapeutic gain
|
7R01CA143971-08
|
$481,438
|
THEODORESCU, DAN
|
CEDARS-SINAI MEDICAL CENTER
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|